Doraid Alrifai
Leicester, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Perspectives on the Treatment of Malignant Pleural Mesothelioma.
Journal: The New England journal of medicine
Published: September 22, 2021
BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma.
Journal: The Journal of biological chemistry
Published: April 14, 2021
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited).
Journal: British journal of cancer
Published: December 09, 2020
Palliative care in mesothelioma: Are current services RESPECT-able enough?
Journal: Thorax
Published: February 11, 2019
Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 03, 2018
Emerging resistance pathways in lung cancer: what has ROS-1 taught us?
Journal: Translational lung cancer research
Published: March 14, 2018
Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.
Journal: eLife
Published: July 07, 2017
Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours.
Journal: Endocrine-related cancer
Published: May 17, 2016
Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells.
Journal: Immunopharmacology and immunotoxicology
Published: October 17, 2015
MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Journal: Expert opinion on investigational drugs
Published: October 18, 2014
A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 16, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026